| Name | Title | Contact Details |
|---|
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
ARIAD is a pharmaceutical company whose vision is to transform the lives of cancer patients with breakthrough medicines.
Culture Biosciences develops automated bioreactor infrastructures and runs it as a service for biotech companies.
Comet Therapeutics addresses these profound unmet medical needs with its CoEnzyme Metabolism (CoMET™) Platform.
Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.